Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Harmony Biosciences Holdings Inc HRMY

Healthcare Biotechnology
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 1 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and High-Dose (HD). In addition, the company’s products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of ...


NDAQ:HRMY - Post by User

Harmony Biosciences Holdings Inc
Bullboard Posts
User Avatar Image
(4)
•••
  • AviseAnalyticsX
Post by AviseAnalyticson Jun 02, 2022 7:51am
178 Views
Post# 34725736

PITOLISANT IS A “PORTFOLIO IN A PRODUCT” OPPORTUNITY!

PITOLISANT IS A “PORTFOLIO IN A PRODUCT” OPPORTUNITY!
Harmony Biosciences, Inc. (NASDAQ: HRMY) is a commercial-stage biopharmaceutical company developing novel therapeutics for rare and orphan diseases, focusing on central nervous system disorders. Pitolisant, its lead product candidate, is a first-in-class histamine 3 (H3) receptor antagonist/inverse agonist that can help treat excessive daytime sleepiness (EDS), narcolepsy, and cataplexy. 
 
We take a look at what's in the pipeline for Harmony Biosciences!

Read on to know more:

https://www.aviseanalytics.com/pitolisant-is-a-portfolio-in-a-product-opportunity/

 
 
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities